1
|
Raja KRM, Kovarova L, Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010; 149:334-51. [DOI: 10.1111/j.1365-2141.2010.08121.x] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
2
|
Warburton P, Joshua DE, Gibson J, Brown RD. CD10-(CALLA)-Positive Lymphocytes in Myeloma: Evidence that they are a Malignant Precursor Population and are of Germinal Centre Origin. Leuk Lymphoma 2009; 1:11-20. [DOI: 10.3109/10428198909042453] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
3
|
Pileri A, Ferrero D, Massaia M, Dianzani U, Boccadoro M. Advances in biology of multiple myeloma: cell kinetics, molecular biology and immunology. Eur J Haematol Suppl 2009; 51:30-4. [PMID: 2697592 DOI: 10.1111/j.1600-0609.1989.tb01489.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Bone marrow plasma cell proliferative activity has been evaluated in a large series of multiple myeloma (MM) patients. This kinetic parameter has been shown to be a useful tool for patient management, and contributes to a correct diagnosis and a selection of high-risk patients who can be offered high-dose chemotherapy. The role of ras oncogenes has been evaluated in the pathogenesis of MM. A point-mutated and activated H-ras oncogene, introduced in a human lymphoblastoid cell line, was able to induce neoplastic transformation and differentiation to plasma cell. Indeed, mutated alleles of ras genes have been detected in a high percentage of myeloma patients in relapse phase. Phenotypical and functional studies have been carried out in T-lymphocyte subsets and an impaired cellular immunity has been detected. Such an impairment was related to the disease status: marked alterations were detected in relapse phase, whereas a partial recovery was observed during remission phase.
Collapse
|
4
|
Kumar S, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, Lust JA, Gertz MA, Greipp PR, Witzig TE. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol 2005; 23:5668-74. [PMID: 16110026 DOI: 10.1200/jco.2005.03.159] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Monoclonal gammopathy of undetermined significance (MGUS) progresses to multiple myeloma or another related plasma cell disorder (PCD) at a rate of approximately 1% per year. Identification of patients with MGUS at high risk of progression will allow development of preventive strategies. We studied the prognostic value of circulating plasma cells (PCs) in patients with MGUS to predict progression. PATIENTS AND METHODS Patients were eligible for this retrospective analysis if they were seen at the Mayo Clinic between 1984 and 1997, were diagnosed with MGUS, and had an analysis of the peripheral blood for circulating PCs by the slide-based immunofluorescence method. Patients were observed for progression to another PCD. RESULTS Three hundred twenty-five patients were eligible and 63 (19%) had circulating PCs. Patients with circulating PCs were twice as likely (hazard ratio, 2.1) to experience progression to another PCD (most commonly myeloma), compared with those without circulating PCs (95% CI, 1.1 to 4.3; P = .03). In patients with circulating PCs, the median progression-free survival was 138 months compared with a median not yet reached for those without circulating PCs (P = .028). The median overall survival also was shorter for those with circulating PCs. Other factors with prognostic value were high levels of M protein and non-immunoglobulin G heavy-chain type. CONCLUSION The presence of circulating PCs, especially when combined with other known prognostic factors such as M protein concentration and immunoglobulin isotype, identify a group of individuals with MGUS at higher risk of progression to overt multiple myeloma.
Collapse
Affiliation(s)
- Shaji Kumar
- Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Shiokawa S, Nishimura J, Uike N, Saburi Y, Suehiro T, Yamamoto K. Clonal identities and multiple isotype transcripts in hematological diseases revealed by a single-strand conformation polymorphism analysis of the immunoglobulin heavy chain messenger signals. Am J Hematol 1999; 62:74-81. [PMID: 10509000 DOI: 10.1002/(sici)1096-8652(199910)62:2<74::aid-ajh2>3.0.co;2-f] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
A single-strand conformation polymorphism (SSCP) analysis of polymerase chain reaction (PCR)-amplified products of immunoglobulin (Ig) heavy chain rearrangements can be used to analyze B cell clonalities and clonal identities of B cells from different samples. However, the usefulness of the PCR-SSCP analysis is not fully assessed in B cell malignancies. For example, we did not know whether the PCR-SSCP method can be used to detect tumor-related clones in peripheral blood of patients with multiple myeloma and Waldenström's macroglobulinemia. In addition, because genomic DNA is used in the PCR-SSCP method, we could obtain no information about the isotype of the expanded B cell clone. In this study, we combined the reverse transcriptase (RT)-PCR of immunoglobulin heavy chain transcripts with an SSCP analysis and thus analyzed eight healthy individuals, five patients with B chronic lymphocytic leukemia, four patients with multiple myeloma and three patients with Waldenström's macroglobulinemia. Clonal B cell populations were detected as discrete bands in the RT-PCR-SSCP analysis that can be readily detected over the background of polyclonal rearrangements. Circulating tumor-related clones were detected in all but one peripheral blood sample from multiple myeloma and Waldenström's macroglobulinemia patients and B cell clones in peripheral blood and bone marrow from these patients showed a similar mobility on SSCP gel. Because the transcripts of different isotypes were separately analyzed, we could thus determine the isotype of B cell clones as well. When monoclonal Igs of different isotypes were detected in the individual samples, we analyzed the relationship of each monoclonal band by excising the band and then further analyzing it by a PCR-SSCP analysis. RT-PCR amplification in conjunction with the SSCP analysis is thus considered to be a useful method to detect and characterize the B cell clones in hematological diseases.
Collapse
MESH Headings
- Aged
- B-Lymphocytes/immunology
- Bone Marrow Cells/immunology
- Bone Marrow Cells/pathology
- DNA Primers
- DNA Probes
- Female
- Gene Rearrangement, B-Lymphocyte, Heavy Chain
- Humans
- Immunoglobulin Heavy Chains/genetics
- Immunoglobulin Isotypes/genetics
- Immunoglobulin M/blood
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Male
- Middle Aged
- Multiple Myeloma/genetics
- Multiple Myeloma/immunology
- Polymorphism, Single-Stranded Conformational
- RNA, Messenger/genetics
- Recurrence
- Reference Values
- Reverse Transcriptase Polymerase Chain Reaction
- Transcription, Genetic
- Waldenstrom Macroglobulinemia/genetics
- Waldenstrom Macroglobulinemia/immunology
Collapse
Affiliation(s)
- S Shiokawa
- Department of Clinical Immunology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita, Japan.
| | | | | | | | | | | |
Collapse
|
6
|
Shiokawa S, Nishimura J, Ohshima K, Uike N, Yamamoto K. Establishment of a novel B cell clonality analysis using single-strand conformation polymorphism of immunoglobulin light chain messenger signals. THE AMERICAN JOURNAL OF PATHOLOGY 1998; 153:1393-400. [PMID: 9811330 PMCID: PMC1853392 DOI: 10.1016/s0002-9440(10)65726-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The remarkable diversity of the complementarity determining region (CDR) 3 of the immunoglobulin (Ig) heavy (H) chain gene rearrangements has been exploited to identify the clonal populations of B cells in B cell malignancies. However, when B cell malignancies of different categories were examined, the overall detection rate was found to be approximately 70%. The development of a simple clonality analysis using Ig light (L) chain CDR3 diversity has been hampered due to the sparseness of knowledge regarding the sequence of Vkappa and Vlambda gene segments and the restriction of L chain CDR3 length. Based on the recently reported Vkappa and Vlambda gene sequences, we designed Vkappa and Vlambda framework 3 consensus primers. We combined the reverse transcriptase polymerase chain reaction (RT-PCR) of IgL chain transcripts with a single-strand conformation polymorphism (SSCP) analysis and then analyzed samples from patients with B cell malignancies. Clonal B cell populations were detected as discrete bands, and identical clones showed a similar mobility in a RT-PCR SSCP analysis. This method was thus found to be a useful supplement to the previously described approach of VH gene amplification for detecting clonal B cell populations. By using SSCP, we were able to determine the clonal identities of B cell expansion in different samples.
Collapse
Affiliation(s)
- S Shiokawa
- Department of Clinical Immunology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita, Japan
| | | | | | | | | |
Collapse
|
7
|
Luque R, Brieva JA, Moreno A, Manzanal A, Escribano L, Villarrubia J, Velasco JL, López-Jiménez J, Cerveró C, Otero MJ, Martínez J, Bellas C, Roldán E. Normal and clonal B lineage cells can be distinguished by their differential expression of B cell antigens and adhesion molecules in peripheral blood from multiple myeloma (MM) patients--diagnostic and clinical implications. Clin Exp Immunol 1998; 112:410-8. [PMID: 9649209 PMCID: PMC1904982 DOI: 10.1046/j.1365-2249.1998.00600.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Human MM is a haematologic disorder characterized by the accumulation of malignant plasma cells (PC), primarily in the bone marrow (BM). Although these cells characteristically home to the BM, in recent years several groups have detected the presence of related malignant B cells in the peripheral blood (PB) which could be implicated in the progression and spread of the disease. However, the proportion and origin of these clonotypic circulating B cells is still controversial. In this study, using a triple-staining flow cytometric procedure and a whole blood lysis method, PB B lineage cells could be divided into two populations according to their distinct repertoires of cell adhesion molecules and B cell antigens in untreated MM patients. The results show that: (i) the percentage and the absolute number of PB CD19+ B cells were decreased in MM patients compared with controls; (ii) the quantity and percentage of B cell antigens (CD20, CD22, CD24, DR, CD138) and adhesion molecules (beta1- and beta2-integrins, CD44, CD54, CD56, CD61 and CD62L) expressed by these PB CD19+ cells of MM patients and healthy subjects were similar and all of them were virtually polyclonal cells; (iii) a very minor circulating CD19-CD38++CD45-/dim subset was also detected which expressed CD138 (B-B4) (high intensity), monoclonal cytoplasmic immunoglobulin (cIg), and was negative for pan-B antigens (CD19, CD20, CD24, DR), surface immunoglobulin (sIg) and several adhesion molecules such as CD62L, CD18 and CD11a; this CD19-CD38++CD45-/dim CD138++ subset was not found in normal blood and exhibited a phenotypic profile which was closely related to that of malignant BM plasma cells, with the exception of the CD56 antigen. Polymerase chain reaction (PCR) analysis of IgH clonotypic rearrangements confirmed these results. We postulate that, in MM patients, circulating B lineage cells may be divided into two different categories: polyclonal CD19+ B cells and a very minor proportion of clonal CD138++ PC that escape from the BM.
Collapse
Affiliation(s)
- R Luque
- Immunología Hospital Ramón y Cajal, Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
San Miguel JF, Garcia-Sanz R, Gonzalez M, Orfao A. Immunophenotype and DNA cell content in multiple myeloma. BAILLIERE'S CLINICAL HAEMATOLOGY 1995; 8:735-59. [PMID: 8845570 DOI: 10.1016/s0950-3536(05)80257-4] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
In this paper three different areas of the biology of multiple myeloma (MM) are reviewed: (1) the immunophenotypic characteristics of plasma cells (PC), (2) the changes in the immunoregulatory cells, and (3) the cell DNA content of PC. Myelomatous PC display a heterogeneous phenotype not only between different patients but also within each patient consistent with the fact that the neoplastic clone is able to undergo a certain degree of differentiation. In addition, PC generally lack surface B cell associated antigens and infrequently show reactivity for non-lineage restricted markers. The B-B4 and CD38 are the two best markers for identifying PC which are crucial for the correct assessment of other antigens by multiple staining procedures. Moreover, some of the antigens present in PC such as CD56, CD20, CD10, CD28 and SIg may have prognostic implications. Whether or not normal PC are phenotypically different from myelomatous PC remains controversial although some antigenic combinations such as CD19-/CD56++ could probably help to identify the malignant nature of PC. Both T and NK cells are markedly altered in MM patients probably reflecting a host-tumour immunological interaction. The reduction in CD4 cells correlates both with advanced clinical stage and poor survival. As far as NK cells are concerned, there is an overall increase in peripheral blood and BM in MM patients but the changes observed are heterogeneous, reflecting the existence of different NK cell subsets. This fact could explain the contradictory results observed in the literature. Accumulating evidence exists that the measurement of cell DNA content by flow cytometry is a useful parameter in the clinical evaluation of MM patients. Between 50 and 70% of MM patients display DNA aneuploidy with the majority of them hyperdiploid. Upon comparing hyperdiploid with diploid patients, the former usually display a better prognosis. The possibility of analysing the cell cycle distribution by using a PI/CD38 double staining technique may be an alternative to other more laborious methods of assessing the PC labelling index. In our experience, patients with > 3% S phase PC have an adverse prognosis and this parameter was the most important independent prognostic criteria for predicting survival.
Collapse
Affiliation(s)
- J F San Miguel
- Department of Haematology, University of Salamanea, Spain
| | | | | | | |
Collapse
|
9
|
Witzig TE, Gertz MA, Lust JA, Kyle RA, Greipp PR. Serial studies of peripheral blood myeloma cells in patients with multiple myeloma: when is the optimal time for stem cell harvest? Leuk Lymphoma 1995; 19:417-22. [PMID: 8590841 DOI: 10.3109/10428199509112199] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
This study serially quantitated monoclonal plasma cells (PC) in the peripheral blood (PB) of 33 patients with multiple myeloma (MM) at diagnosis, after therapy, and at relapse using a sensitive immunofluorescence technique. The goal was to learn which disease phase is best for harvesting PB stem cells free of monoclonal PC. In 24 chemotherapy responders, 88% (21/24) had circulating PC at diagnosis; after therapy, 63% (15/24) had none, 33% (8/24) had < 3 x 10(6)/L, and only one had > or = 3 x 10(6)/L. In nine cases who failed to respond to initial chemotherapy, 89% (8/9) had high levels (> or = 3 x 10(6)/L) of circulating PC at diagnosis that remained high after therapy. In the relapse phase, 88% (21/24) had circulating PC and 63% (15/24) had high numbers. This study demonstrates that the PB is least likely to have circulating monoclonal PC during the period after successful chemotherapy. Patients who fail to respond to initial chemotherapy or are in relapse are likely to have tumor cells in the PB.
Collapse
Affiliation(s)
- T E Witzig
- Division of Internal Medicine and Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
| | | | | | | | | |
Collapse
|
10
|
The detection and clinical significance of monoclonality in lymphoproliferative disorders. ACTA ACUST UNITED AC 1995. [DOI: 10.1016/s0968-6053(05)80057-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
11
|
Massaia M, Pileri A. T cells in multiple myeloma: is this a reliable population to count on as antitumor effector cells? Leuk Lymphoma 1995; 17:63-70. [PMID: 7773163 DOI: 10.3109/10428199509051704] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Multiple Myeloma (MM) is still a long way from being cured. Disease evolution has been associated with a number of phenotypic and functional alterations in T cells, indicating that a progressive deterioration of cellular immunity might facilitate the negative outcome. Despite these correlations, specific interactions between tumor and T cells have been demonstrated indicating that a population liable to be exploited as antitumor effector cells exists in vivo. This review aims at recording some evidence obtained in our laboratory demonstrating that MM T cells, despite the variety of their alterations, can still generate potent antitumor activity. Adequate stimulation, however, is required to exploit this ability.
Collapse
Affiliation(s)
- M Massaia
- Dipartimento di Medicina e Oncologia Sperimentale, Universita' di Torino, Italy
| | | |
Collapse
|
12
|
Witzig TE. Detection of malignant cells in the peripheral blood of patients with multiple myeloma: clinical implications and research applications. Mayo Clin Proc 1994; 69:903-7. [PMID: 8065198 DOI: 10.1016/s0025-6196(12)61798-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
OBJECTIVE To review the methods for detecting and quantifying malignant cells in the peripheral blood (PB) and to correlate such cells with the activity of multiple myeloma (MM). DESIGN Results of personal investigations and studies reported in the literature were summarized. RESULTS MM is characterized by a monoclonal proliferation of plasma cells in the bone marrow. Although usually clinically inapparent, these plasma cells can circulate in the PB and be detected by use of sensitive immunofluorescence, flow cytometric, or molecular genetic techniques. The detection of these cells is clinically important because they correlate with disease activity. As MM progresses, the plasma cells appear in greater numbers in the PB. When patients respond to chemotherapy, the number of circulating plasma cells decreases. CONCLUSION Determining the molecular, immunologic, and morphologic characteristics of the circulating cells is important for improving our understanding of the pathogenesis of MM and deciding which cells to target therapeutically.
Collapse
Affiliation(s)
- T E Witzig
- Division of Hematology and Internal Medicine, Mayo Clinic Rochester, Minnesota 55905
| |
Collapse
|
13
|
Abstract
OBJECTIVE To review biologic factors that may be useful in determining prognosis in patients with myeloma. DESIGN The currently available clinical variables and staging systems were assessed for their predictive value in myeloma, and newly proposed prognostic factors were summarized. RESULTS Because some patients with myeloma may potentially benefit by new, more intensive therapies such as stem cell transplantation or may have prolonged survival with standard therapy, determining factors that would distinguish such patients is important. Independent prognostic factors such as the plasma cell labeling index and beta 2-microglobulin have repeatedly outperformed other prognostic clinical variables and can be combined into a system that identifies poor, intermediate, and good prognostic groups of patients with myeloma. New factors are needed to improve on the predictive value of these two variables. Studies of the biologic features of myelomas have led to the discovery of soluble interleukin 6 receptor (sIL 6R) in the serum. sIL 6R enhances the myeloma cell response to interleukin 6, a central growth factor that affects myeloma cell proliferation. Preliminary studies by the Eastern Cooperative Oncology Group show that sIL 6R predicts survival independent of the plasma cell labeling index and beta 2-microglobulin. Other proposed independent prognostic factors include cytokines and their soluble receptors, regulatory T cells, circulating myeloma cells, myeloma cell precursors, and markers of proliferation, apoptosis, and drug resistance. CONCLUSION Because of wide variation in duration of survival, the prognosis of patients with myeloma, a fatal bone marrow plasma cell neoplasm, cannot yet be adequately predicted. Better prognostic factors are needed for stratification in clinical trials, counseling of patients, and designing of new therapeutic trials.
Collapse
Affiliation(s)
- P R Greipp
- Division of Hematology and Internal Medicine, Mayo Clinic Rochester, Minnesota 55905
| |
Collapse
|
14
|
Abstract
OBJECTIVE To describe the immunophenotype of normal and myelomatous plasma cells (PCs) and the changes in immunoregulatory nonmyelomatous cells in multiple myeloma (MM). DESIGN The cell surface markers (antigens) associated with this common cancer were reviewed. MATERIAL AND METHODS Immunophenotypic characterization of both normal PCs and their counterpart malignant hematopoietic cells can be achieved by using monoclonal antibodies and either flow cytometry or immunocytochemical techniques. RESULTS Normal PCs are heterogeneous and express, in addition to cytoplasmic immunoglobulins, the antigens CD9, CD10, CD13, CD19, CD20, CD33, CD38, and D-related human leukocyte antigen (HLA-DR). This heterogeneity also occurs in malignant PCs. Myelomatous PCs may express, in addition to CD38 (the most typical PC marker), the antigens CD9, CD10, HLA-DR, and CD20. Other non-B-cell lineage markers such as myeloid (CD13, CD14, CD15, CD33, CD41, and glycophorin A), T-cell (CD2 and CD4), and natural killer-associated (CD56) antigens, as well as CD23, CD24, CD25, CD37, CD39, CDw40, CD45R, CD71, and certain unclustered antigens (R1-3, PCA-1, PCA-2, PC1, 62B1, 8A, 8F6, and MM4), have been noted in myelomatous PCs. The presence of these antigens in the myeloma cells may have a prognostic value--for example, the expression of CD20 and of myelomonocytic antigens (CD11b, CD13, CD14, CD15, and CD33) may be related to a poor prognosis. The adverse prognostic implication of the expression of CD10 initially described in MM has not been subsequently confirmed. Patients with MM may have mononuclear cells in their peripheral blood that express the same antigens as those expressed by the myeloma cells in their bone marrow. The presence of such cells or their therapy-associated decrease or disappearance may be related to the prognosis of patients with MM. CONCLUSION The presence of cell surface markers on PCs and their prognostic significance in patients with MM warrant further investigation.
Collapse
|
15
|
Joshua D, Wolf M, Matthews J, Tan L, Sheridan W, Pilkington G, Page F. Peripheral blood lymphocyte surface antigen expression and prognosis in myeloma: Australian Leukaemia Study Group Study. Leuk Lymphoma 1994; 14:303-9. [PMID: 7950919 DOI: 10.3109/10428199409049682] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The Australian Leukaemia Study Group myeloma study (MM1) aimed to determine the prognostic significance of clinical and immunophenotypic markers in patients with multiple myeloma. All patients were treated with standard dose melphalan and prednisone. Seventy-four patients were entered and the median survival was 27 months. Serum beta 2-microglobulin (beta 2M) and albumin levels were the only significant clinical factors influencing survival (p = 0.007 and p = 0.008, respectively). Patients with raised levels of CD38+ lymphocytes at presentation had a significantly shorter survival than patients with normal levels (p = 0.01, logrank test, median 19 months vs 33 months). CD38 antigen expression was independent of beta 2M but patients with raised levels of CD38 had significantly lower levels of albumin than patients with normal levels (p = 0.001) which may explain their poorer survival. Salmon and Durie stage was not associated with antigen expression. No other B-cell antigens (CD10, CD19, CD20, CD21, CD22, CD23, FMC1 or FMC7) or plasma cell antigens tested (PCA-1) were found to be associated with prognosis. Patients who achieved plateau phase had a better prognosis than those who did not (p = 0.04 in a landmark analysis). Patients who achieved plateau phase following an objective response appeared to have a better prognosis than those who were in plateau phase at presentation (p = 0.09 in a landmark analysis). Light chain isotype suppression (LCIS) was not associated with a significant survival advantage and did not correlate with any known prognostic indicator.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- D Joshua
- Haematology Department, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | | | | | | | | | | | | |
Collapse
|
16
|
Omedè P, Boccadoro M, Fusaro A, Gallone G, Pileri A. Multiple myeloma: 'early' plasma cell phenotype identifies patients with aggressive biological and clinical characteristics. Br J Haematol 1993; 85:504-13. [PMID: 8136273 DOI: 10.1111/j.1365-2141.1993.tb03340.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The immunological phenotype of bone marrow myeloma cells and peripheral blood lymphocytes was evaluated in 38 untreated myeloma patients. A striking increase of monotypic cells expressing the same light chain as the M component was observed in bone marrow from 18/38 (47%) patients. A two-colour analysis clarified that the majority of myeloma cells co-expressed plasma cell and B lymphocyte markers (cyIg, CD38, CD56 and sIg), and were regarded as early-plasma cells (early-PC). In the remaining patients, myeloma cells expressed plasma cell markers only (late-PC). Phenotype corresponded to a distinct morphological pattern: early-PC showed a lympho-plasmocytoid feature with significantly lower diameters than late-PC (12.1 v 14.8 microns, P < 0.007). Moreover, the plasma cell labelling index was significantly increased in early-PC patients (1.2 v 0.5%, P < 0.04). In peripheral blood from patients with early-PC, monotypic cells co-expressing sIg and CD38, CD56, but not CD19, were also detected. These data suggest a recirculation of early-PC. Myeloma cells maintained their phenotypic pattern during the course of the disease. This observation suggests that the degree of maturation is an intrinsic characteristic of the myeloma cell population in individual patients. The evaluation of prognostic factors, such as beta 2-microglobulin, C-reactive protein and neopterin, showed a statistically significant increase in the early-PC patients, suggesting a poor outcome. In conclusion, myeloma cell phenotype allows identification of a myeloma variant with aggressive biological and clinical characteristics.
Collapse
Affiliation(s)
- P Omedè
- Divisione di Ematologia dell'Università di Torino, Ospedale Molinette, Italy
| | | | | | | | | |
Collapse
|
17
|
Everaus H, Hein M, Zilmer K. Possible imbalance of the immuno-hormonal axis in multiple myeloma. Leuk Lymphoma 1993; 11:453-8. [PMID: 8124218 DOI: 10.3109/10428199309067940] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
A comparative study of some immunologic aspects and hormonal balance was performed on 49 multiple myeloma (MM) patients and 29 healthy persons. Functional immunoregulatory imbalances were evident in the majority of patients with MM, as demonstrated by a significant reduction in the mitogenic response of peripheral blood lymphocytes (PBL) to phytohemagglutinin, increased mean stimulation indices of PBL to pisum sativatum agglutinin, wheat germ agglutinin (WGA) and dextran sulphate. Our results appear to provide important evidence in support of the existence of hormonal imbalance in MM: increased cortisol levels, augmented concentrations of follicle stimulating hormone, luteinizing hormone and 17 beta-estradiol and an increased estrogen to androgen ratio in male patients; decreased estrogen values and estrogen to androgen ratios were evident in female patients. Triiodothyronine and thyroxine mean concentrations were also found to be markedly diminished in MM patients. Our studies suggest some potentially important interactions between the immune and endocrine systems in multiple myeloma.
Collapse
Affiliation(s)
- H Everaus
- Department of Internal Medicine, University of Tartu, Estonia
| | | | | |
Collapse
|
18
|
Jensen GS, Mant MJ, Pilarski LM. Sequential maturation stages of monoclonal B lineage cells from blood, spleen, lymph node, and bone marrow from a terminal myeloma patient. Am J Hematol 1992; 41:199-208. [PMID: 1384318 DOI: 10.1002/ajh.2830410311] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
In order to fully understand the complexity of the monoclonal B lineage cells in multiple myeloma, it is necessary to evaluate the extent to which these cells are resident in solid lymphoid tissues and the phenotypic differences and similarities as compared to the circulating or bone marrow derived B lineage cells. Peripheral blood mononuclear cells from a patient with multiple myeloma were obtained 8 and 3 days prior to death, and mononuclear cells from lymph nodes, spleen, and bone marrow were obtained at autopsy. Rapid changes in the stage of differentiation of blood late-stage B lineage cells towards mature end-stage plasma cells were observed during the last week prior to death. Lymphoid cells within the blood comprised very few T cells, sub-normal numbers of monocytes, and 80% of B lineage cells which were at a late stage of differentiation. Shortly before death, plasma cells were found in the peripheral blood, indicating progression to plasma cell leukemia. At autopsy, the monoclonal B lineage cells in lymph node, spleen, and bone marrow represented different stages of terminal B cell differentiation. In each tissue, the B lineage cells were at an earlier differentiation stage, as defined phenotypically, than the circulating B lineage cells found in blood 3 days prior to death. Analysis of B cell markers and CD45 was used to define the differentiation stage of the relevant B cell populations, revealing a series of differentiation stages. The least mature B lineage cells (CD45hi) were found in lymph node. However, the CD45 isoform expressed was CD45R0, unlike most normal lymph node B cells. More differentiated B lineage cells (CD45med) were found in the bone marrow, and three sequential stages of pre-plasma cells were found in the spleen (CD45bright, CD45moderate, and CD45low-neg), all of which were CD45R0+. The B cells in normal spleen and bone marrow are CD45RA+. The presence of monoclonal B lineage cells in spleen was confirmed by Southern blotting. The B lineage cells from peripheral blood 3 days prior to death were approaching an end-stage plasma cell stage (CD45low/-). On B lineage cells from the various myeloma tissues, a concomitant loss of CD11b and increasing density of CD29 were observed as a function of progression to terminally differentiated stages.
Collapse
Affiliation(s)
- G S Jensen
- Department of Immunology, University of Alberta, Edmonton, Canada
| | | | | |
Collapse
|
19
|
|
20
|
Gonzalez M, San Miguel JF, Gascon A, Moro MJ, Hernandez JM, Ortega F, Jimenez R, Guerras L, Romero M, Casanova F. Increased expression of natural-killer-associated and activation antigens in multiple myeloma. Am J Hematol 1992; 39:84-9. [PMID: 1550111 DOI: 10.1002/ajh.2830390203] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The expression of both natural-killer (NK)-associated and activation antigens was studied by flow cytometry in the peripheral blood of 47 untreated multiple myeloma (MM) patients. A significant increase in both absolute and relative numbers of CD57 positive cells as well as in the proportion of CD16 and CD11b cells was observed in patients with MM, specially in those in early stages of the disease (clinical stages I and II), suggesting a possible surveillance mechanism in response to an emerging malignant clone. Additional double stainings showed that strong CD16+ NK cells coexpress the CD56, CD11b, and CD2 antigens, while they lacked CD3, CD5, and WT31 antigens. Moreover, the previously reported increase in CD8 cells present in MM would be mainly due to a subset of CD8 cells that coexpress the CD57 Ags. The expression of activation antigens, especially CD38, was increased in peripheral blood lymphocytes of MM patients, the differences reaching statistical significance both in absolute and relative numbers in those cases with high numbers of CD16 NK cells and thus suggesting that these cells are functionally activated. These results reveal the existence of an increase in NK and activated cells in the peripheral blood of myeloma patients that may reflect a host's immunological mechanism in an attempt to modulate tumor cell growth.
Collapse
Affiliation(s)
- M Gonzalez
- Servicio de Hematología, Hospital Clínico, Salamanca, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Huang LQ, Tang JZ, Shen GX, Wang XL. Peripheral blood and bone marrow lymphocyte subsets in patients with multiple myeloma. JOURNAL OF TONGJI MEDICAL UNIVERSITY = TONG JI YI KE DA XUE XUE BAO 1990; 10:73-6. [PMID: 2145443 DOI: 10.1007/bf02887864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
A panel of monoclonal antibodies (McAb) from the Wu series was used to characterize lymphocyte subsets of peripheral blood (PB) from 9 patients with multiple myeloma (MM) by means of indirect immunofluorescence assay. In 7 of these patients bone marrow (BM) cells were also studied. Abnormal distribution of T lymphocyte subsets was observed in these patients, and the alterations were quite similar in both PB and BM. A significant increase in the proportion of WUT8+ cells (P less than 0.001) and a reduced WuT4/WuT8 ratio (P less than 0.001) were found in patient group. In both PB and BM of patients, WuT10+ cell counts were significantly higher than normal (P less than 0.001). There was a good correlation between BM WuT10+ cells and BM myeloma cells (r = 0.76, P less than 0.05), whereas no correlation was found between PB WuT10+ cells and BM myeloma cells. The significance of abnormal T-cell subset distribution and elevated WuT10+ cells in MM is discussed.
Collapse
Affiliation(s)
- L Q Huang
- Department of Internal Medicine, Tongji Hospital, Tongji Medical University, Wuhan
| | | | | | | |
Collapse
|
22
|
Abstract
When a patient presents with monoclonal gammopathy, a wide variety of clinical conditions must be considered. The importance of distinguishing accurately between patients with stable monoclonal gammopathies and those with overt multiple myeloma cannot be over-emphasised. The bone marrow examination with plasma cell labeling index, and newer techniques such as magnetic resonance imaging and computed tomography can improve diagnostic discrimination. In difficult cases, the detection of small numbers of circulating myeloma cells, the peripheral blood B-cell labeling index, and light chain isotype suppression may bring better diagnostic resolution. These tests may also be used to help assess disease activity. If the diagnosis is multiple myeloma, prediction of outcome assumes clinical importance. There are widely disparate survivals among patients with different clinical presentations. Standard clinical assays or a combination of these as in clinical staging do not provide sufficient prediction of outcome but are routinely available and therefore widely used. Independent predictive tests such as the plasma cell labeling index and beta 2-microglobulin improve prognostic accuracy. Ploidy analysis and immunophenotyping are additional variables that may assume more importance as the results of ongoing studies appear. Other promising approaches include detection of oncogene and multiple drug resistance gene expression. All such techniques will become more relevant as we apply more intensive treatment earlier in the disease course, particularly for the younger myeloma patients in whom the prognosis is poor.
Collapse
Affiliation(s)
- P R Greipp
- Division of Hematology and Internal Medicine, Mayo Clinic, Rochester MN 55905
| |
Collapse
|
23
|
Abstract
Peripheral blood mononuclear cells from 28 patients with multiple myeloma (MM) and nine patients with monoclonal gammopathy of unknown significance (MGUS) were studied by immunoglobulin gene analysis. Clonal immunoglobulin gene rearrangements in peripheral blood mononuclear cells (PBIGRA) were demonstrated in 10 of the 28 MM patients (36%). Bone marrow and peripheral blood mononuclear cells were studied simultaneously in five of these 10 patients, and identical gene rearrangements were demonstrated in both. The incidence of such gene arrangements was higher in patients with active disease (cases at presentation or relapsed = 10/19 [47%]) compared to remission status (0/9) and higher in untreated (47%) compared to treated patients (11%) (P less than 0.05). Patients with this phenomenon had higher serum calcium levels (P less than 0.001), and higher bone marrow plasma cell counts (P less than 0.05). Serum creatinine and beta 2-microglobulin were also higher but did not reach statistical significance. None of the patients with monoclonal gammopathy of uncertain significance had gene arrangements. Our findings confirm that circulating B lymphocytes are part of the malignant clone in MM and their presence correlates with high tumour volume.
Collapse
Affiliation(s)
- E K Chiu
- Department of Haematology, Royal Free Hospital School of Medicine, London
| | | | | | | |
Collapse
|